Ngm Biopharmaceuticals Inc NGM

NAS: NGM | ISIN: US62921N1054 4/04/2024

1,540 USD (-1,28%)

(-1,28%) 4/04/2024

Grafiek Ngm Biopharmaceuticals Inc

Grafiek Ngm Biopharmaceuticals Inc

1 dag1d -1,28%
1 week1w 0,00%
1 maand1m -1,28%
3 maanden3m 10,79%
6 maanden6m 83,33%
1 jaar1j -60,51%
5 jaar5j -90,32%

Ngm Biopharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

27 februari 2024 · SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AA, NGM, MDC, KAMN · Persbericht

27 september 2023 · Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel Medicines · Persbericht

9 februari 2021 · NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition · Persbericht

12 januari 2021 · NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology · Persbericht

6 januari 2021 · NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock · Persbericht

4 januari 2021 · NGM Bio Announces Proposed Offering of Common Stock · Persbericht

Profiel Ngm Biopharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ngmbio.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: David Woodhouse

Werknemers: 285

Aandelen Ngm Biopharmaceuticals Inc

Effecten: 83,46 miljoen

Winst per aandeel (12 maand): PLUS

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe